Earnings

Harmony Biosciences Reports Q3 WAKIX Sales Of $269M, Driven By Strong Demand With 400 Net Patient Adds; Appoints Peter Anastasiou As CEO, Effective January 1, 2027

Nov 4, 2026 · 07:38 AM ET· updated 2h ago

Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending Dose Study Reinforces Favorable Safety, Tolerability and Pharmacokinetic Profile Observed in Single-Ascending Dose StudyResults from Phase 1b Study in

Why It Matters

Harmony Biosciences sold $269 million of WAKIX in three months. More customers bought the medicine, which shows people want their product.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

HRMY33.58

-3.44 (-9.29%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.